J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577)

Read the full 237 word article

User Sign In